Qamar, Arman
Libby, Peter
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T32HL007604)
American Heart Association (18SFRN3390085, 18SFRN33960262)
Article History
First Online: 27 June 2019
Compliance with Ethical Standards
:
: Arman Qamar declares that he has no conflict of interest.Peter Libby reports other from Kowa Pharmaceuticals, other from Amgen, other from AstraZeneca, other from Esperion Therapeutics, other from Ionis Pharmaceuticals, grants and other from Novartis, other from Pfizer, other from Sanofi-Regeneron, other from XBiotech, Inc., other from Corvidia Therapeutics, personal fees from DalCorPharmaceuticals, other from IFM Therapeutics, other from Olatec Therapeutics, other from Medimmune, and other from XBiotech, Inc.
: This article does not contain any studies with human or animal subjects performed by any of the authors.